PREFACE | INTRODUCTION | CHAPTER 1 | CHAPTER 2 | CHAPTER 3 | CHAPTER 4 | CHAPTER 5 | CHAPTER 6 | CHAPTER 7 | CHAPTER 8 | CHAPTER 9 | CHAPTER 10 | CHAPTER 11 | CHAPTER 12 | CHAPTER 13 | CHAPTER 14 | CHAPTER 15 | REFERENCES
Cancer - A Philosophical Treatise
We must go back to basics to answer the question
"what is cancer?". We are so conditioned to going into a state
of shock at the very mention of the word that we hardly think rationally
of just what cancer is. It is, stated very simply, the uncontrolled
proliferation of cells. Normally, our immune system can handle foreign
cells, toxins, and abnormal, cancerous cells. However, due to a multiplicity
of factors, perhaps genetic predisposition, poor diet, toxic environmental
attack, recreational abuse, negativity and depression, our "resistance"
weakens, abnormal cells multiply and start to spread, somehow oblivious
to normal control mechanisms.
Nowhere is the split between allopathic and holistic
medicine more pronounced than in diseases such as cancer. Western science,
stuck in the notion "one disease, one cause", spends billions
of dollars in many highly focused races to find a cure for a "dis-ease"
of a body. Hence the "search and destroy" methodology of chemotherapy,
radiation therapy, radical surgery, all in the sincere desire that to
be healed, the cancer must be destroyed.
A holistic approach to healing considers all factors
of the individual: psychological/spiritual, emotional, environmental
as well as physical. Where is the cancer? What in that person's life
has caused him to create a cancer in that part of the body? What is
the physical and genetic disposition of the person, his parents? What
has been his diet? How stressful is his work? Is he fulfilled emotionally
and spiritually? Does he exercise?
Diagnosis and treatment of cancer would ideally
utilize, in a cooperative fashion, the most appropriate techniques of
modern medicine and/or complementary therapies, with the patient playing
an active role in his treatment and healing (9). This type of treatment
would use to maximum advantage technological advances of modern medicine
as well as the accumulated wisdom of traditional healing practices.
The approaches used with Germanium in the East and
West exemplify almost perfectly the dichotomy between the two healing
traditions. On the one hand, the Asai Germanium clinic prescribes organic
Germanium, along with a non-acid forming diet and stress counselling
for its cancer patients. On the other extreme, North American oncology
groups administer Spirogermanium in intravenous drips to cancer patients
(117), who have already undergone every other option before being admitted
to the Germanium clinical trial.
Chapter 13 compares
and evaluates in detail, the philosophy and practice of each of these
approaches, as well as those more in the middle. This chapter summarizes
the scientific research which documents organic Germanium as a therapeutic
agent in cancer treatment.
Germanium - Advantages Of Being
A Food And A Drug
There are normally several distinct stages whereby
a potential cancer drug is tested before it can be made available. If
the substance demonstrates anticancer activity in a number of in vitro
(in the test tube) assays, then studies on animals will be conducted.
If these studies demonstrate promising results, then experiments and
trials will be conducted with actual human cancer patients. Because
organic Germanium is a natural substance with virtually no demonstrated
toxicity (see chapter on Safety), Germanium is classified as a food
supplement and not a drug, which has enabled faster progress in establishing
its therapeutic action in humans for many serious illnessess, including
cancer. Thus, treatment of human cancer patients over almost two decades
has occurred in parallel with the careful scientific studies in animals,
establishing its anticancer action, resulting in a wealth of documentation
from the human side, as well as laboratory data. There are business
and philosophical issues deriving from this question of "food or
drug", which will be addressed in Chapter 12.
Putting together the cancer research studies of
the three organic Germanium compounds, Ge-132, Sanumgerman and Spirogermanium,
at the cellular level, in animals and human cancer patients, the evidence
for organic Germanium's anticancer properties is solid and reproducible.
This chapter will highlight the research results in these various areas.
- The Allium test uses actively dividing plant cells
to measure the anticancer or oncostatic activity of a potential anticancer
substance. Sanumgerman, when analyzed by this procedure, showed the
characteristics of an active compound (36,54,62).
- Tests with various laboratory cancerous cell lines
demonstrated that Spirogermanium significantly inhibited DNA, RNA and
protein synthesis of these cancer cells at very low concentrations (88,118).
- Further characterization of organic Germanium's
mode of action at the cellular and molecular level, showed that Germanium
compounds inhibited viral (HSV-1) replication in vitro and blocked the
synthesis of DNA in hepatoma 22A and ovarian cancer cells (39,40,68).
- Sanumgerman's antitumour activity with several
types of cancers has been documented in mice. In one study, the group
of mice which received Sanumgerman had a 20% incidence of tumours, compared
to 50% in the control group (13). Also, Sanumgerman administered to
mice with carcinoma of the colon survived longer (61). In other studies,
Sanumgerman showed positive results against colon, lung and Myeloma
type cancers (60).
- In studies with rats, Spirogermanium was shown
to increase the lifespan by 500% of animals with Walker type carcinoma
- Ge-132 has shown significant antitumour activity
against a wide spectrum of tumours (53,58,71,101), which has been elegantly
shown to be mediated by activation of immune mechanisms, including macrophages,
natural killer cells, interferon and T-suppressor cells (see also chapter
The above-cited animal studies with organic Germanium
compounds were conducted by a variety of established scientific groups
around the world, in accordance with scientifically accepted protocols,
such as those set down by the National Cancer Institute, USA. The results
have been published in learned refereed scientific journals, attesting
to the fact that the methodology and data analysis were subjected to
controls associated with scientific metholody. Although this in itself
is no guarantee of a substance's efficacy in humans, it does attest
to the fact that organic Germanium compounds demonstrate significant
anticancer activity in laboratory animals infected with a wide range
of different cancers.
Human Cancer Patients
- Clinical trials on lung cancer showed a statistically
significant effect of Ge-132 upon life prolongation, tumour regression
and overall improvement in performance status and immunological parameters.
A double-blind controlled study for unresectable lung cancer was commenced
in 1980 (71). The patients were divided into classes, depending on the
type of cancer. The treatments consisted either of chemotherapy plus
Ge-132, or chemotherapy plus a placebo, administered double-blind, meaning
that neither the patient nor the doctor knew whether the individual
was receiving Germanium or the placebo. Interim results to date revealed
a significant difference between the placebo and Ge-132 in the proportion
of partial and complete responses to treatment with organic Germanium.
- A technical document issued by the Asai Germanium
Research Institute, compiles clinical and research data on the pharmacological,
immunological and toxicological properties of Ge-132 (30). The long
list of studies, trials and investigators in the Appendix attests to
the intense research activity ongoing in Japan, to "evaluate strictly
the therapeutic efficacy of Ge-132".
- A clinical study of Sanumgerman's effectiveness
against ovarian malignancy was conducted with 6 women, aged 44-64, who
had been operated for malignant tumours of the ovaries and uterus (85).
The well-being of all these patients improved considerably, and they
experienced considerable relief from pain. The remarkable analgesic
(pain-relieving) properties of organic Germanium are reviewed in chapter
. In five out of the six women, there was no exudate formation in the
abdominal or inner pelvic cavity; a slight exudate was observed in the
- A Phase I clinical trial was conducted with 35
patients with a variety of cancers, with intravenously administered
Spirogermanium (88,89). This trial was conducted in order to define
a tolerated dosage and to determine anticancer activity. Several of
the patients experienced mild and transient side effects such as dizziness
which were all resolved within a few minutes to several hours. There
was no evidence of cumulative toxicity, nor of bone marrow depression.
One patient showed a partial response in the palpable lymph nodes for
- A Phase II trial for patients with lymphoma-proliferative
disease (non-Hodgkin's lymphoma and Hodgkin's disease) was conducted
with Spirogermanium. Out of 17 patients, 5 (30%) demonstrated an objective
response, including 2 complete responses. No hematological toxicity
was observed (88).
Excerpted Case Histories
- Reduction in the size of a splenic tumour was achieved
after 3 week's Sanumgerman, orally administered to a 62 year old woman
with myeloproliferate syndrome (55).
- An 18-year old male with embryonal cancer of the
testicles and lung filae, undergoing a variety of therapeutic regimes,
including Sanumgerman, recovered, with no metastases up to the present
- A 55 year old woman who had been operated on for
Sigmcarcinoma, developed metastases in the stomach, kidney, mesenterium
and liver. Following cytostatic (chemo) therapy, she received Sanumgerman
treatment. Dark-field analysis of her red blood picture was closely
monitored. After 3 months of treatment with Sanumgerman, there was a
significant decrease in erythrombic development, with considerable improvement
in cell respiration. Four years after the operation, there was NO trace
of liver metastases, although the size of the tumour and lymphatic ganglion
slightly increased (77).
- A 78 year old male with colon cancer and liver
metastases was operated on in 1978 and again in 1979. Liver metastases
were discovered in 1982, upon which biological therapy, a strict cancer
diet and Sanumgerman therapy was initiated. After 1 year, there were
no metastases in a clinical examination, which was the same situation
a further 3 years later (120).
- A 54 year old man with a large bean-size cancerous
growth on the right lung, after taking anticancer drugs lost his appetite
and was losing his strength. Five weeks after taking 500 mg daily Ge-132,
X-rays showed absolutely no trace of cancer, the dry cough had disappeared
and his overall condition improved to his former state of good health
These few case histories represented a small fraction
of the "anecdotal" evidence that has accumulated, attesting
to organic Germanium's therapeutic effectiveness in treating cancer.
Not all cancer patients receiving organic Germanium have been cured;
minimal therapeutic effect has been noted in several clinical trials
with intravenously administered Spirogermanium. As is discussed in in
Chapter 13, this may in part reflect the trial selection and administration
However almost invariably a general overall improvement
in the quality of life occurs, due in large part to organic Germanium's
ability to relieve pain. Anecdotal case histories are not considered
by scientists to be proof of a substance's efficacy, because it cannot
be rigorously proved that the patient was cured by the particular substance
in question. Greater agreement about methodology in clinical testing
must occur if an integration between western science and holistic medicine
can occur. Holistic medicine takes as a given that the true healer is
the individual himself, who, in taking whatever treatment he does, is
enabling his body's own healing powers to restore him to health. Combining
scientific rigour with holistic compassion will increase an individual's
course of therapeutic progress.